Ballen Medical & Wellness
- IV Therapy
- Ketamine Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
Greenwood Village, CO
Ketamine Therapy clinics in Greenwood Village
Greenwood Village has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Colorado has a mature ketamine clinic market; the Colorado Medical Board enforces monitoring standards during infusions. Most Greenwood Village clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Greenwood Village only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Greenwood Village, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Greenwood Village sits in the premium range: single IV infusions run 600 to 1,000 dollars, a full 6 session protocol lands at 3,600 to 6,000, and Spravato copays depend on insurance coverage. A reputable Greenwood Village ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Mind Spa Denver
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Oxygen Therapy
- Ketamine Therapy
Axis Integrated Mental Health - Denver Tech Center TMS and Ketamine
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Regulatory context
A note on Colorado's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Colorado Proposition 122 / Natural Medicine Health Act (2022)
Decriminalized personal use of psilocybin, psilocyn, DMT, ibogaine, and mescaline (non-peyote) for adults 21+; authorized state-licensed Healing Centers for psilocybin-assisted therapy, with MDMA access permitted by state rule after June 2026. -
SB 23-290 Natural Medicine Regulation and Legalization
Implementing legislation establishing the Natural Medicine Division within DORA and the licensure framework for facilitators, healing centers, cultivators, and product manufacturers.
Colorado Healing Centers began licensing and operating in late 2024 and early 2025. The Colorado Department of Regulatory Agencies (DORA) Natural Medicine Division oversees facilitator licensure, healing center operations, testing, and track-and-trace. Federal law still classifies psilocybin as Schedule I, so DEA enforcement risk remains theoretical. The Colorado Medical Board regulates ketamine prescribing. Ryan Haight Act applies to telehealth ketamine.